

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

APPROVAL FOR CLINICAL TRIAL OF THE GROUP'S PRODUCT DUPILUMAB INJECTION

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that the application for the clinical trial of dupilumab bio-similar developed by Zhuhai United Bio-Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the Company, was approved for indication of atopic dermatitis by the China National Medical Products Administration with reference number CXSL2600180.

Dupilumab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody indicated for the treatment of atopic dermatitis, particularly moderate-to-severe atopic dermatitis in patients whose disease is inadequately controlled with topical therapies or for whom topical therapies are not advisable. Dupilumab specifically binds to the interleukin-4 receptor alpha subunit (IL-4R α), thereby inhibiting signaling for interleukin-4 (IL-4) and interleukin-13 (IL-13), suppressing type 2 inflammatory responses. In addition, dupilumab reduces the secretion of inflammation-related cytokines, lowers immunoglobulin E (IgE) levels, and improves skin and mucosal barrier function. It is an important targeted therapy for the treatment of type 2 inflammatory diseases including atopic dermatitis.

This approval marks a further advancement in the Company's research and development in the field of inflammatory and autoimmune disease treatment. In the future, the Company will continue to commit itself to the research and development of new products, and focus on enhancing its competitiveness and creativity in the biopharmaceutical industry, with a view of creating more benefits for the Company and its shareholders.

By Order of the Board
The United Laboratories International Holdings Limited
Tsoi Hoi Shan
Chairman

Hong Kong, 22 April 2026

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.